Skip to Content

Rozita Bagheri-Yarmand, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

 Studying the mechanisms of oncogenic functions of RET tyrosine kinase receptor, tumor suppressor role of Activating Transcription factor 4 (ATF4), developing novel combination therapy for medullary thyroid cancer (MTC),  RET function in epigenetic control of gene expression in MTC

Education & Training

Degree-Granting Education

1995 University of Paris XIII, Paris, France, PHD, Cancer Biology
1990 University of Paris VII, Paris, France, MS, Biochemistry
1987 University of Paris VII, Paris, France, BS, Biochemistry

Postgraduate Training

1999-2002 Research Fellowship, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
1995-1996 Research Fellowship, Cancer Biology, French Institute of Health and Medical Research U353, Paris, France


Academic Appointments

Instructor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-2004
Assistant Professor, Department of Cell Biology, University of Paris XIII, Paris, France, 1996-1999
Director of Core Facility, Department of Nuclear Medicine, Hospital Avicenne, Bobigny, France, 1996-1999

Institutional Committee Activities

member, Animal care and use committee, 9/2011-9/2015

Honors and Awards

2012 Second place Junior Faculty poster award, Division of internal Medicine, Research Retreat, MD Anderson Cancer Center
2006 Career Development Award, University of Texas M. D. Anderson Cancer Center
1997 Distinguished Scientist Award, "Banque de la vie, Recherche Cancer" Foundation
1995 Post-doctoral Fellowship Award, Martine Midy Foundation
1991-1995 Pre-doctoral Fellowship Award, University of Paris XIII

Selected Publications

Peer-Reviewed Original Research Articles

1. Bagheri-Yarmand R, Sinha KM, Gururaj AE, Ahmed Z, Rizvi YQ, Huang SC, Ladbury JE, Bogler O, Williams MD, Cote GJ, Gagel RF. A Novel Dual Kinase Function of the RET Proto-oncogene Negatively Regulates ATF4-Mediated Apoptosis. Journal of Biological Chemistry 290:11749-11761, 1/2015. PMCID: PMC25795775.
2. Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. e-Pub 7/2013. PMID: 23722650.
3. Molli PR, Li DQ, Bagheri-Yarmand R, Pakala SB, Katayama H, Sen S, Iyer J, Chernoff J, Tsai MY, Nair SS, Kumar R. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol 190(1):101-14, 7/2010. e-Pub 7/2010. PMCID: PMC2911675.
4. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70(12):5085-95, 6/2010. e-Pub 6/2010. PMCID: PMC2946214.
5. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70(12):5074-84, 6/2010. e-Pub 6/2010. PMCID: PMC2888821.
6. Balasenthil S, Gururaj AE, Talukder AH, Bagheri-Yarmand R, Arrington T, Haas BJ, Braisted JC, Kim I, Lee NH, Kumar R. Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res 67(15):7132-8, 8/2007. PMID: 17671180.
7. Bagheri-Yarmand R, Balasenthil S, Gururaj AE, Talukder AH, Wang YH, Lee JH, Kim YS, Zhang X, Jones DM, Medeiros LJ, Stephens LC, Liu YJ, Lee N, Kim I, Kumar R. Metastasis-associated protein 1 transgenic mice: a new model of spontaneous B-cell lymphomas. Cancer Res 67(15):7062-7, 8/2007. PMID: 17671172.
8. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118(11):2703-10, 6/2006. PMID: 16381000.
9. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 5(6):575-85, 6/2004. PMID: 15193260.
10. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep 5(2):154-60, 2/2004. PMID: 14749719.
11. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10(2):658-67, 1/2004. PMID: 14760089.
12. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9(8):3198-203, 8/2003. PMID: 12912973.
13. Bagheri-Yarmand R, Vadlamudi RK, Kumar R. Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution. J Biol Chem 278(19):17421-9, 5/2003. PMID: 12611881.
14. Wang RA, Vadlamudi RK, Bagheri-Yarmand R, Beuvink I, Hynes NE, Kumar R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol 161(3):583-92, 5/2003. PMID: 12732616.
15. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2(4):345-51, 4/2003. PMID: 12700278.
16. Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors. Clin Cancer Res 8(10):3285-9, 10/2002. PMID: 12374700.
17. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418(6898):654-7, 8/2002. PMID: 12167865.
18. Hamma-Kourbali Y, Vassy R, Starzec A, Le Meuth-Metzinger V, Oudar O, Bagheri-Yarmand R, Perret G, Crepin M. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes. J Biol Chem 276(43):39748-54, 10/2001. PMID: 11514538.
19. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, Kumar R. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 276(31):29403-9, 8/2001. PMID: 11382770.
20. Bagheri-Yarmand R, Hamma-Kourbali Y, Bissieres P, Morere JF, Crepin M. Carboxymethyl benzylamide dextran and tamoxifen combination inhibits tumor growth and angiogenesis. Clin Cancer Res 7(6):1805-11, 6/2001. PMID: 11410523.
21. Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, Bagheri-Yarmand R, Mendelsohn J, Kumar R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem 276(13):9699-704, 3/2001. PMID: 11121407.
22. Bagheri-Yarmand R, Moretti JL, Baba K, Ozker K, Jozefonvicz J, Crepin M. Breast carcinoma cell uptake and biodistribution of technetium-99m-carboxymethyl benzylamide dextran. Anticancer Res 21(1A):373-8, 2001. PMID: 11299764.
23. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3(1):30-7, 2001. PMID: 11146623.
24. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 275(50):39451-7, 12/2000. PMID: 10967114.
25. Bittoun P, Bagheri-Yarmand R, Chaubet F, Crepin M, Jozefonvicz J, Fermandjian S. Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor-binding studies. Biochem Pharmacol 57(12):1399-406, 6/1999. PMID: 10353261.
26. Bagheri-Yarmand R, Kourbali Y, Rath AM, Vassy R, Martin A, Jozefonvicz J, Soria C, Lu H, Crepin M. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. Cancer Res 59(3):507-10, 2/1999. PMID: 9973189.
27. Bagheri-Yarmand R, Kourbali Y, Mabilat C, Morere JF, Martin A, Lu H, Soria C, Jozefonvicz J, Crepin M. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer 78(1):111-8, 7/1998. PMID: 9662260.
28. Bagheri-Yarmand R, Kourbali Y, Morere JF, Jozefonvicz J, Crepin M. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor beta1 and platelet-derived growth factor-BB. Cell Growth Differ 9(6):497-504, 6/1998. PMID: 9663468.
29. Bagheri-Yarmand R, Liu JF, Ledoux D, Morere JF, Crepin M. Inhibition of human breast epithelial HBL100 cell proliferation by a dextran derivative (CMDB7): interference with the FGF2 autocrine loop. Biochem Biophys Res Commun 239(2):424-8, 10/1997. PMID: 9344845.
30. Liu J, Bagheri-Yarmand R, Xia Y, Crepin M. Modulations of breast fibroblast and carcinoma cell interactions by a dextran derivative (CMDB7). Anticancer Res 17(1A):253-8, 1997. PMID: 9066661.
31. Bagheri-Yarmand R, Bittoun P, Champion J, Letourneur D, Jozefonvicz J, Fermandjian S, Crepin M. Carboxymethyl benzylamide dextrans inhibit breast cell growth. In Vitro Cell Dev Biol Anim 30A(12):822-4, 12/1994. PMID: 7534590.
32. Bagheri-Yarmand R, Morere JF, Letourneur D, Jozefonvicz J, Israel L, Crepin M. Inhibitory effects of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res 12(5):1641-6, 9/1992. PMID: 1280032.

Invited Articles

1. Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol 30(5 Suppl 16):30-7, 10/2003. PMID: 14613024.
2. Kumar, R, Bagheri-Yarmand, R. HER2 signaling in angiogenesis. Seminars in Oncology 28:27-32, 2001.


1. Bagheri-Yarmand R, Lahiri S, Wan X, Navone N, Logothetis CJ, Gagel RF, Sinha, KM. A Novel Epigenetic regulator histone demethylase NO66 promtes prostate cancer bone metastasis. Proceeding AACR 106th annual meeting, 2015. e-Pub 2015.
2. Bagheri-Yarmand R, Navone N, Wan X, Ganesh VK, Logothetis C, Gagel RF. Histone demethylase NO66 overexpression promotes proliferative and invasive potential of prostate cancer cells and causes osteolytic bone lesions in mice. proceeding AACR chromatin and epigenetics in cancer, 2015.
3. Rozita Bagheri-Yarmand, Gilbert J Cote, Robert F Gagel. Nuclear RET Increases Survival by Suppression of ATF4-mediated Apoptosis. 14th world Multiple Endocrine Neoplasia, Vienna, 2014.
4. Bagheri-Yarmand R, Cururaj, AE, Williams M, Ahmed Z, Ladbury JE, Bogler O, Huang SC, Cote GJ, Gagel RF. RET tyrosine kinase receptor represses NOXA transcription and prevents genotoxic or endoplasmic reticulum stress-induced apoptosis. American Association for Cancer Research, Washington DC, 2013. e-Pub 4/2013.
5. Bagheri-Yarmand R, Huang SC, Cote GJ, GagelRF. Novel Mechanism of RET-mediated regulation of cell cycle progression in medullary thyroid cancer. 12th International workshop on multiple endocrine Neoplasia, 9/2010.
6. Bagheri-Yarmand R, Biernacka A, Nano-Webb A, Hunt K, Keyomarsi K. Low-Molecular-Weight Cyclin E shortens mitosis and causes chromosome missegregation through premature activation of Cdc25C. Gordon Conference, Cell Growth & Proliferation, Colby, ME, 2009.
7. Bagheri-Yarmand R, Keyomarsi K. Overexpression of full length or low molecular weight of cyclin E leads to differential G2/M transition and mitotic defects through deregulation of cdc25C. American Association for Cancer Research, Denver, 2009.
8. Bagheri-Yarmand R, Hunt K, Keyomarsi. Activating transcription factor 4 is a novel regulator of the cell cycle through direct interaction with p27kip1 and CDK4 in breast cancer. American Association for Cancer Research, San Diego, 2008.
9. Bagheri-Yarmand R, Keyomarsi K. Activatng transcription factor 4 is a novel modulator of the cell cycle through direct interaction with p27kip1. Gordon Conference. Cell Growth & Proliferation, Biddeford, ME, 2007.
10. Bagheri-Yarmand R, Keyomarsi K. The low molecular weight forms of Cyclin E and p53 cooperate to induce spindle abnormalities and failure of cytokinesis in breast cancer cells. American Association for Cancer Research, Washington DC, 2006.
11. Bagheri-Yarmand R, Kumar R. A component of the human Arp2/3 complex induces centrosome amplification, abnormal mitotic spindles and breast cancer tumorigenesis. American Association for Cancer Research, Anaheim, 2005.
12. Crepin M, Dibenedetto R, Bagheri-Yarmand R, Starzec A, Vassy R, Perret G. Prevention of breast tumor angiogenesis and metastasis by cytostatic molecules in relevant mouse models. Breast Cancer Research 5:52, 2003.

Grant & Contract Support

Title: Overcoming resistance to tyrosine kinase inhibitors therapy through simultaneous targeting of the integrated stress response pathway
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/8/2015 - 7/31/2017
Title: ATF4, a novel putative tumor suppressor gene in medullary thyroid cancer
Funding Source: American Thyroid Association
Role: Principal Investigator
Duration: 7/1/2010 - 6/30/2012

Last updated: 1/27/2016